Linaclotide

Linaclotide is reported to bind guanylate cyclase-C on the luminal side of intestinal epithelial cells. Activation of this receptor increases cyclic GMP, which supports chloride and bicarbonate secretion into the gut and reduces sodium reabsorption. The resulting fluid shift can soften stool and accelerate intestinal transit. The source also describes a local, cyclic-GMP-linked effect on gut pain signaling, with minimal absorption into systemic circulation.

The source summarizes linaclotide as having regulatory-grade clinical evidence. It reports two large randomized, double-blind, placebo-controlled phase 3 IBS-C trials of roughly 800 participants each, lasting 12 and 26 weeks, where 290 mcg once daily outperformed placebo on FDA co-primary endpoints combining abdominal pain reduction with complete spontaneous bowel movements. It also reports chronic idiopathic constipation research over 12 weeks using lower doses such as 72 mcg. Serious adverse events were described as uncommon and not clearly higher than placebo, while diarrhea was the main tolerability issue and a frequent reason for discontinuation.